Cris Loiren Rodriguez

Array ( [id] => 16533332 [patent_doc_number] => 10875916 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-29 [patent_title] => Nucleic acid molecules encoding monoclonal antibodies specific for IL-17F [patent_app_type] => utility [patent_app_number] => 16/153091 [patent_app_country] => US [patent_app_date] => 2018-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 59 [patent_figures_cnt] => 50 [patent_no_of_words] => 58836 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16153091 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13867579 [patent_doc_number] => 20190030130 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => HUMAN SKIN SUBSTITUTES EXPRESSING IL-12 [patent_app_type] => utility [patent_app_number] => 16/150048 [patent_app_country] => US [patent_app_date] => 2018-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15600 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16150048 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17604036 [patent_doc_number] => 11332507 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-17 [patent_title] => IL-22 Fc fusion proteins [patent_app_type] => utility [patent_app_number] => 16/128008 [patent_app_country] => US [patent_app_date] => 2018-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 69 [patent_figures_cnt] => 175 [patent_no_of_words] => 52475 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16128008 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16582866 [patent_doc_number] => 20210017268 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => METHODS FOR TREATING ALCOHOLIC LIVER DISEASE, ALCOHOL-INDUCED BRAIN INJURY AND REDUCING ALCOHOL ADDICTION [patent_app_type] => utility [patent_app_number] => 16/639514 [patent_app_country] => US [patent_app_date] => 2018-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33787 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16639514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17258525 [patent_doc_number] => 20210371510 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => Methods for Treating TNFa-Related Diseases [patent_app_type] => utility [patent_app_number] => 16/643377 [patent_app_country] => US [patent_app_date] => 2018-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22443 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16643377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16126009 [patent_doc_number] => 10696747 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-30 [patent_title] => IL2R common gamma chain antibodies [patent_app_type] => utility [patent_app_number] => 16/112008 [patent_app_country] => US [patent_app_date] => 2018-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 67 [patent_figures_cnt] => 68 [patent_no_of_words] => 23136 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16112008 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16756607 [patent_doc_number] => 10975144 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-13 [patent_title] => CDNA encoding a monoclonal anti-IL-32 antibody and methods for the production of the antibody [patent_app_type] => utility [patent_app_number] => 16/107889 [patent_app_country] => US [patent_app_date] => 2018-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 12 [patent_no_of_words] => 32145 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16107889 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16336565 [patent_doc_number] => 10787510 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-29 [patent_title] => Methods of treating cancer using an IL-21 agonist [patent_app_type] => utility [patent_app_number] => 16/101976 [patent_app_country] => US [patent_app_date] => 2018-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 21912 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 213 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16101976 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18101234 [patent_doc_number] => 11541103 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-03 [patent_title] => Interleukin-21 mutein/ anti-PD-1 antibody conjugates [patent_app_type] => utility [patent_app_number] => 16/054035 [patent_app_country] => US [patent_app_date] => 2018-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 78 [patent_no_of_words] => 65042 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16054035 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590069 [patent_doc_number] => 20180346583 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => METHOD OF TREATING PSORIASIS USING AN IL-17 RECEPTOR ANTIBODY FORMULATION [patent_app_type] => utility [patent_app_number] => 16/053564 [patent_app_country] => US [patent_app_date] => 2018-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 111777 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16053564 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14072395 [patent_doc_number] => 20190085085 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => ANTI-IL-6 RECEPTOR ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/041976 [patent_app_country] => US [patent_app_date] => 2018-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57006 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16041976 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590027 [patent_doc_number] => 20180346562 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => ANTIBODIES DIRECTED AGAINST INTERLEUKIN-33 (IL-33) [patent_app_type] => utility [patent_app_number] => 16/042476 [patent_app_country] => US [patent_app_date] => 2018-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12824 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16042476 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13461781 [patent_doc_number] => 20180282433 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-04 [patent_title] => USE OF IL-17A AND IL-17F CROSS-REACTIVE MONOCLONAL ANTIBODIES FOR TREATING INFLAMMATORY DISEASES [patent_app_type] => utility [patent_app_number] => 16/009653 [patent_app_country] => US [patent_app_date] => 2018-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35937 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16009653 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13476513 [patent_doc_number] => 20180289799 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-11 [patent_title] => Conjugates of GM-CSF and IL-7, and Compositions Thereof [patent_app_type] => utility [patent_app_number] => 16/007392 [patent_app_country] => US [patent_app_date] => 2018-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23194 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16007392 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15765923 [patent_doc_number] => 20200113979 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-16 [patent_title] => Protein Kinase C-delta targeted therapy for treating radiation injury [patent_app_type] => utility [patent_app_number] => 16/621720 [patent_app_country] => US [patent_app_date] => 2018-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22780 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16621720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13533747 [patent_doc_number] => 20180318416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-08 [patent_title] => BINDING MOLECULES SPECIFIC FOR IL-21 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/004795 [patent_app_country] => US [patent_app_date] => 2018-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32975 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16004795 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14132389 [patent_doc_number] => 20190100584 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-04 [patent_title] => AMINO ACID SEQUENCES DIRECTED AGAINST IL-17A, IL-17F AND/OR IL-17A/F AND POLYPEPTIDES COMPRISING THE SAME [patent_app_type] => utility [patent_app_number] => 16/002135 [patent_app_country] => US [patent_app_date] => 2018-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 115127 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16002135 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14216939 [patent_doc_number] => 20190120854 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => DIAGNOSIS AND TREATMENTS RELATING TO TH2 INHIBITION [patent_app_type] => utility [patent_app_number] => 15/992115 [patent_app_country] => US [patent_app_date] => 2018-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43221 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15992115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16091091 [patent_doc_number] => 20200199532 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => COMPOSITIONS AND METHODS FOR EXPANDING EX VIVO NATURAL KILLER CELLS AND THERAPEUTIC USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/614132 [patent_app_country] => US [patent_app_date] => 2018-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11700 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16614132 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16476230 [patent_doc_number] => 10851158 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-01 [patent_title] => Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof [patent_app_type] => utility [patent_app_number] => 15/985660 [patent_app_country] => US [patent_app_date] => 2018-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 17450 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15985660 [rel_patent_id] =>[rel_patent_doc_number] =>)